[Press Release]PharmAbcine, HREC Approval announcement Austin Health

23 Aug 2019
PharmAbcine, HREC Approval announcement Austin Health
Press Release

PharmAbcine, Inc.  Korea announced that the Austin Health Human Research Ethics Committee (HREC) notified the company an approval of a phase 2 clinical trial of Olinvacimab (TTAC-0001) in recurrent glioblastoma patients progressed on Bevacizumab including therapy.  It is a multicenter, open-label study to evaluate the safety and efficacy of Olinvacimab(TTAC-0001), a fully human monoclonal antibody targeting VEGFR-2 (KDR). Olinvacimab was granted ODD by USFDA for primary and  recurrent GBM and the phase II clinical trials that are being prepared in Australia as well as in USA are the key clinical studies tofacilitate the processto bring the drug to market.  The phase II clinical trial will be initiated at Austin Health in Australia.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.